US2012034195A1PendingUtilityA1

Placental stem cells derive from post-partum manmalian placenta, and uses and methods of treatment using said cells

Assignee: HARIRI ROBERT JPriority: Feb 13, 2002Filed: Oct 17, 2011Published: Feb 9, 2012
Est. expiryFeb 13, 2022(expired)· nominal 20-yr term from priority
A61P 9/10A61P 3/10A61P 9/00A61P 37/06A61P 25/00A61P 29/00A61P 25/28A61P 25/02C12N 2500/90A61M 2210/1466A61M 1/02A61M 2202/0462A61P 19/00C12N 5/0607C12N 2509/00A61K 35/545A61M 2210/1458C12N 5/0605C12N 5/0068A61K 35/28A61K 35/50C12N 2533/90A61P 17/02A61K 48/00A61P 21/00A61K 35/51
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides compositions and methods of using placental stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells. The placental stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the present invention, the placental stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow. The placental stem cells and the mixed populations of placental stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses.

Claims

exact text as granted — not AI-modified
1 .- 82 . (canceled) 
     
     
         83 . A method of treating an individual who has amyotrophic lateral sclerosis, comprising administering to the individual a therapeutically effective amount of isolated human placental stem cells, wherein said placental stem cells are OCT-4 +  and CD34 − , wherein OCT-4 is octamer binding protein 4 (POU5F). 
     
     
         84 . The method of  claim 83 , wherein said placental stem cells are OCT-4 + , CD34 − , SSEA3 −  and SSEA4 − . 
     
     
         85 . The method of  claim 83 , wherein said placental stem cells are OCT-4 +  and CD34 − , and additionally SH3 +  or SH4 + . 
     
     
         86 . The method of  claim 85 , wherein said isolated placental stem cells are SH3+ and SH4 + . 
     
     
         87 . The method of  claim 86 , wherein said isolated human placental stem cells are SSEA3 −  and SSEA4 − . 
     
     
         88 . The method of  claim 83 , wherein said placental stem cells are OCT-4 + , CD34 − , CD10 + , CD29 + , CD44 + , CD45 − , CD54 + , CD90 + , SH3 + , SH4 + , SSEA3 − , and SSEA4 − .

Join the waitlist — get patent alerts

Track US2012034195A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.